1. What Is CRISPR?

CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats. It was not invented, it was discovered. In 1987, Japanese microbiologist Yoshizumi Ishino first observed mysterious repetitive sequences in bacterial DNA. Scientists confirmed only in 2007 that these sequences formed an adaptive immune system that bacteria had evolved to remember and destroy previously encountered viruses.

The transformative leap came in 2012, when Jennifer Doudna at UC Berkeley and Emmanuelle Charpentier published a landmark paper in Science. They demonstrated that the CRISPR-Cas9 system could be reprogrammed using a synthetic guide RNA to cut any DNA sequence, essentially converting a bacterial immune system into universal molecular scissors capable of editing the genome of any living organism.

Core Components

How CRISPR Works: Five Stages

Next-Generation CRISPR Variants

2. Why the World Needs CRISPR

Around 80% of rare diseases are genetic in origin caused by mutations in single genes. For decades, medicine could only treat downstream consequences, manage symptoms or replace deficient proteins. The root genetic cause remained untouchable. CRISPR changes this at platform level.

Unlike previous therapeutic approaches, CRISPR operates as a platform. The same core machinery can be redirected to any gene in any patient simply by changing the guide RNA sequence. A company that demonstrates the safety and efficacy of CRISPR delivery for one liver-based rare disease has, in principle, cleared the path for dozens more — using largely the same platform, delivery vehicle, and manufacturing infrastructure.

3. CRISPR Patents: The Battle for Ownership

Intellectual property rights over foundational CRISPR technology represent one of the most commercially consequential patent disputes in biotechnology history. At stake are licensing fees and royalty streams potentially worth billions of dollars, control over which companies can develop CRISPR therapeutics and on what terms, and the degree to which patent monopolies translate into treatment prices beyond reach for most patients.

Patent Milestone Timeline

4. Patent Landscape: Filing Trends and Global Distribution

Gene editing and cell therapy patent applications grew steadily from 593 in 2020 to a peak of 928 in 2023, before declining to 897 in 2024 and 759 in 2025. The peak filing momentum concentrated between 2022 and 2024 reflects accelerating clinical validation and commercial investment. The moderation from 2024 reflects consolidation of foundational positions rather than reduced innovation.

Top Assignees - Institutional Dominance

MIT (175, 17%), University of California (172, 17%), and the Broad Institute (170, 17%) dominate with near-equal shares, together accounting for over half of all patent activity among the top 10. Regeneron Pharmaceuticals is the only purely commercial pharmaceutical company among the top 10 assignees, reflecting the field's deep academic roots.

Geographic Distribution - US and China Lead

The United States dominates with 3,091 priority filings, followed by China at 1,394 together accounting for the overwhelming majority of first filings globally. The European Patent Office (228) and South Korea (121) represent the next significant contributors, while India, Singapore, Japan, and Australia contribute smaller but meaningful volumes.

5. CPC Classification Analysis

C12N2310/20 (CRISPR systems) dominates with 2,055 patents confirming CRISPR-based editing as the primary technology focus followed by C12N9/22 (ribonucleases/Cas proteins) at 1,715 and A61P35/00 (antineoplastic agents) at 1,526, reflecting oncology as the leading therapeutic indication. C12N15/113 (guide RNA technologies) at 1,469 underscores the centrality of non-coding nucleic acids to the platform.

6. The First Approved CRISPR Drug - CASGEVY

In December 2023, CASGEVY (exagamglogene autotemcel) became the world's first approved CRISPR-based medicine. It received simultaneous regulatory authorization from the UK MHRA, the US FDA, and the European EMA for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia in patients aged 12 and older.

CASGEVY uses CRISPR-Cas9 to edit a patient's own haematopoietic stem cells outside the body, reactivating fetal haemoglobin production to compensate for the defective adult haemoglobin that causes both diseases. Clinical trial data through 2024 showed approximately 90% of treated patients remaining free from severe vaso-occlusive crises for more than 12 consecutive months after infusion, with a mean VOC-free duration of 29.3 months.

7. The Clinical Pipeline

Beyond CASGEVY, the CRISPR therapeutic pipeline is advancing rapidly. The most advanced program is Intellia Therapeutics' NTLA-2001 for transthyretin amyloid cardiomyopathy (hATTR), which completed Phase III enrolment with a filing planned for the second half of 2026. If approved, it would be the first in vivo CRISPR therapy administered directly into the body rather than requiring cells to be edited externally.

8. Conclusion

CRISPR-Cas9 has come a long way in a remarkably short time — from a bacterial immune mechanism observed in a laboratory to a medicine that can rewrite a child's DNA and give them a chance at a normal life. The approval of CASGEVY in December 2023 was not just a scientific achievement; it was proof that gene editing can move from discovery to patient bedside.

The patent data tells the story of how much the world has invested in this technology. Filings grew from 593 in 2020 to a peak of 928 in 2023. The United States and China together account for the overwhelming majority of foundational filings. UC Berkeley, MIT, the Broad Institute, and Harvard together account for nearly half of all CRISPR patents underlying the central role that academic research has played in building this field.

Yet the long-running patent dispute between UC Berkeley and the Broad Institute, still unresolved after more than a decade, remains a reminder that groundbreaking science inevitably raises difficult questions about ownership, access, and who ultimately benefits. CPC data confirms that cancer treatment and CAR-T immunotherapy are the most active patent areas, while nucleic acid delivery, lipid nanoparticles, and precision editing tools like base editing signal where the next wave of innovation is heading.